Shazia Malik, MD
Psychiatry · Saint Louis, MONPI 1477552206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 401 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$1K
- Validus Pharmaceuticals LLC$535
- Alkermes, Inc.$502
- Otsuka America Pharmaceutical, Inc.$416
- plus $2K from 19 others
Across 7 payments — averaging $13,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$95K
- Livanova USA, Inc.$1K
What the payments were for
- Food & beverage$7,21399%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 90 | $1,316 |
| Sunovion Pharmaceuticals Inc. | 67 | $1,043 |
| AbbVie(2 entities) | 66 | $1,008 |
| Validus Pharmaceuticals LLC | 11 | $535 |
| Alkermes, Inc. | 14 | $502 |
| Otsuka America Pharmaceutical, Inc. | 23 | $416 |
| Orexo US, Inc. | 19 | $382 |
| Teva Pharmaceuticals USA, Inc. | 10 | $333 |
| E.r. Squibb & Sons, L.L.C. | 20 | $317 |
| Vanda Pharmaceuticals Inc. | 10 | $222 |
| Neurocrine Biosciences, Inc. | 10 | $208 |
| Johnson & Johnson | 20 | $193 |
| Supernus Pharmaceuticals, Inc. | 11 | $190 |
| Lundbeck LLC | 6 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Braeburn Inc. | 4 | $84 |
| Axsome Therapeutics, Inc. | 5 | $83 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Harmony Biosciences LLC | 1 | $41 |
| Noven Therapeutics, LLC | 2 | $33 |
| UCB, Inc. | 1 | $32 |
| SK Life Science, Inc. | 1 | $30 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $21 |
| Corium, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$904
- Equetro$304
- AUSTEDO$248
- ARISTADA INITIO$226
- LATUDA$125
How this compares
$7,288 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $137,717 |
| CaplytaLumateperone Tosylate | 70 | $97,860 |
| Abilify MaintenaAripiprazole | 25 | $70,395 |
| VraylarCariprazine Hcl | 40 | $65,098 |
| TrintellixVortioxetine Hydrobromide | 68 | $48,048 |
| VivitrolNaltrexone Microspheres | 21 | $34,046 |
| Lurasidone Hcl | 92 | $26,996 |
| SpravatoEsketamine Hcl | 11 | $13,855 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 86 | $13,462 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,290 |
| Carbamazepine ErCarbamazepine | 54 | $6,832 |
| Quetiapine Fumarate | 298 | $6,037 |
| Adderall XrDextroamphetamine/Amphetamine | 14 | $4,927 |
| Olanzapine | 164 | $3,976 |
| Asenapine Maleate | 13 | $3,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $208 | $137,71717 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,316 | $97,86070 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $416 | $70,39525 claims |
| AbbVieVraylar | $1,008 | $65,09840 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $95 | $48,04868 claims |
| Alkermes, Inc.Vivitrol | $502 | $34,04621 claims |
| Johnson & JohnsonSpravato | $193 | $13,85511 claims |
| Axsome Therapeutics, Inc.Auvelity | $83 | $12,29012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.